Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T16:34:36.056Z Has data issue: false hasContentIssue false
  • English
  • Français

Change in neuroleptic prescribing practice

Published online by Cambridge University Press:  02 January 2018

James P. Warner ,
Richard Slade  and
Thomas R. E. Barnes
James P. Warner*
Affiliation:
Academic Department of Psychiatry, Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2QG
Richard Slade
Affiliation:
Manchester Royal Infirmary, Oxford Road, Manchester M13 9BX
Thomas R. E. Barnes
Affiliation:
Department of Academic Psychiatry, Horton Hospital, Epsom, Surrey KT19 8PZ
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Concerns about the use of high doses of neuroleptic medication prompted an audit of prescriptions of these drugs in a large psychiatric hospital. Following an initial audit in 1991 of 196 patients, a follow-up of 192 patients was undertaken in 1993. A significant reduction in levels of neuroleptic medication was found, although doses still tended to remain high.

Type
Audit
Information
Psychiatric Bulletin , Volume 19 , Issue 4 , April 1995 , pp. 237 - 239
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1995

References

Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79–91.Google Scholar
Barnes, T. R. E. & Bridges, P. K. (1980) Disturbed behaviour induced with high dose antipsychotic drugs. British Medical Journal 274–275.Google Scholar
Hirsch, S. R. & Barnes, T. R. E. (1994) Clinical use of high-dose neuroleptics. British Journal of Psychiatry, 164, 94–96.CrossRefGoogle ScholarPubMed
Lelliott, P. (1994) Clinical audit in psychiatry. Hospital Update, 20, 82–91.Google Scholar
Mehtonen, O. P., Aranko, K., Malkonen, L. et al (1991) A survey of sudden death associated with the use of antipsychotic or antidepressant drugs- 49 cases in Finland. Acta Psychiatrica Scandinavica, 84, 58–64.Google Scholar
Reardon, G. T., Rifkin, A., Schwartz, A. et al (1989) Changing patterns of neuroleptic usage over a decade. American Journal of Psychiatry, 146, 726–729.Google Scholar
Rey, M-J., Schulz, P., Costa, C. et al (1989) Guidelines for the dosage of neuroleptics 1. chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology, 4, 95–104.Google Scholar
Rifkin, A., Doddi, S., Karajgi, B. et al (1991) Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166–170.Google Scholar
Thompson, C. (1994) The use of high-dose antipsychotic medication. British Journal of Psychiatry, 164, 448–458.Google Scholar
Van Putten, T & Marder, S. R. (1987) Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48 (supplement 9), 13–19.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.